HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical evaluation of execution of early goal directed therapy in septic shock].

AbstractOBJECTIVE:
To evaluate the efficacy of early goal directed therapy (EGDT) in septic shock.
METHODS:
Two hundred and three patients with septic shock were assigned into treatment group (n=98) and control group (n=105). According to the state of organ function at the beginning of treatment and multiple organ dysfunction syndrome (MODS) evaluation scores, each group was categorized into three strata: stratum A (mild organ dysfunction), stratum B (medium organ dysfunction) and stratum C (severe organ dysfunction). Mortality and incidence of organ dysfunction in each group were analyzed.
RESULTS:
At stratum A, the mortality and incidence of organ dysfunction in treatment group were significantly lower than those of control group [27.78% (15/54 cases) vs. 37.50% (18/48 cases), 31.48% (17/54 cases) vs. 43.75% (21/48 cases), both P<0.05]. There was no significant difference between treatment group and control group in patients of stratum B [75.86% (22/29 cases) vs. 76.92% (20/26 cases), 55.17% (16/29 cases) vs. 57.69% (15/26 cases)] and stratum C [93.33% (14/15 cases) vs. 96.77% (30/31 cases), 40.00 % (6/15 cases) vs. 41.93% (13/31 cases), all P>0.05].
CONCLUSION:
In the earlier period of septic shock, EGDT can remarkably decrease the patients'mortality and incidence of organ dysfunction, but can not improve survival rate and prognosis in patients in advanced stage of septic shock.
AuthorsZheng-yu He, Yuan Gao, Xiang-rui Wang, Yan-nan Hang
JournalZhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue (Zhongguo Wei Zhong Bing Ji Jiu Yi Xue) Vol. 19 Issue 1 Pg. 14-6 (Jan 2007) ISSN: 1003-0603 [Print] China
PMID17207356 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Humans
  • Multiple Organ Failure (etiology, therapy)
  • Prognosis
  • Shock, Septic (complications, mortality, therapy)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: